Globus Medical, Inc. with ticker code (GMED) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $100.00 and $80.00 suggesting an average Analsyt target price of $92.38. Given that the stocks previous close was at $83.09 this indicates there is a potential upside of 11.2%. Also worth taking note is the 50 day moving average now sits at $77.29 and the 200 day moving average is $66.73. The total market capitalization for the company now stands at 11.35B. The current share price for the company is: $83.32 USD
The potential market cap would be $12,614,558,509 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 134.39, revenue per share of $18.22 and a 4.73% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
